AstraZeneca Non Current Assets Total from 2010 to 2024

AZN Stock   10,062  93.00  0.93%   
AstraZeneca PLC's Non Current Assets Total are increasing over the years with slightly volatile fluctuation. Overall, Non Current Assets Total are expected to go to about 79.9 B this year. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
1993-12-31
Previous Quarter
78.9 B
Current Value
80.8 B
Quarterly Volatility
22.3 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many indicators such as . AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
This module can also supplement various AstraZeneca PLC Technical models . Check out the analysis of AstraZeneca PLC Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in AstraZeneca Stock

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.